Status:
COMPLETED
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
Lead Sponsor:
EMD Serono
Conditions:
Parkinson's Disease
Dyskinesia
Eligibility:
All Genders
30+ years
Phase:
PHASE2
Brief Summary
The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (do...
Eligibility Criteria
Inclusion
- Male or Female
- The subject is an out-patient
- Age 30 years or above
- Dyskinesias present during more than 25% of the waking day
- Dyskinesias at least moderately disabling
- Written informed consent
Exclusion
- Pregnancy and/or lactation
- Participation in another study within the last 30 days
- Dementia or other psychiatric illness that prevents provision of informed consent
- History of allergic disorders such as asthma
- Known hypersensitivity to the study treatment(s)
- Known hypersensitivity to ACTH
Key Trial Info
Start Date :
July 1 2002
Trial Type :
INTERVENTIONAL
End Date :
July 1 2003
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT00314288
Start Date
July 1 2002
End Date
July 1 2003
Last Update
January 23 2017
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Fountain Valley, California, United States
2
Sunnyvale, California, United States
3
Miami, Florida, United States
4
Tampa, Florida, United States